Pharma Equity Group A/S Cl A Cash Flow Conversion Efficiency

Latest as of December 2024: -0.136x

Pharma Equity Group A/S Cl A cash flow conversion efficiency. Based on the latest financial reports, Pharma Equity Group A/S Cl A (PEG) has a cash flow conversion efficiency ratio of -0.136x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr-6.66 Million ≈ $-1.04 Million USD) by net assets (Dkr48.88 Million ≈ $7.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Pharma Equity Group A/S Cl A (2009–2025)

Cash flow conversion efficiency of Pharma Equity Group A/S Cl A from 2009 to 2025. This chart illustrates how Pharma Equity Group A/S Cl A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Pharma Equity Group A/S Cl A stock quote for real-time trading data and today's change.

Pharma Equity Group A/S Cl A Cash Flow Conversion Ratio Explained

Pharma Equity Group A/S Cl A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Pharma Equity Group A/S Cl A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pharma Equity Group A/S Cl A ranked by their cash flow conversion efficiency. Also see market value of Pharma Equity Group A/S Cl A for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
KR Motors Co. Ltd.
KO:000040
0.032x
Vinpai SAS
PA:ALVIN
-0.313x
IDT Australia Ltd
AU:IDT
-0.047x
FIPP S.A.
PA:FIPP
0.002x
Foxx Development Holdings Inc.
NASDAQ:FOXX
-0.030x
Aguia Resources Ltd
AU:AGR
-0.050x
Pegasus Heights Bhd
KLSE:4464
0.018x
Excel Realty N Infra Limited
NSE:EXCEL
3.473x

Annual Cash Flow Conversion Efficiency for Pharma Equity Group A/S Cl A (2009–2025)

The table below shows the annual cash flow conversion efficiency of Pharma Equity Group A/S Cl A from 2009 to 2025. Review Pharma Equity Group A/S Cl A (PEG) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-09-30 Dkr25.47 Million
≈ $3.99 Million
Dkr-17.66 Million
≈ $-2.76 Million
-0.693x -48.23%
2024-09-30 Dkr48.88 Million
≈ $7.65 Million
Dkr-22.86 Million
≈ $-3.58 Million
-0.468x +28.72%
2023-09-30 Dkr25.33 Million
≈ $3.96 Million
Dkr-16.62 Million
≈ $-2.60 Million
-0.656x -951.34%
2022-09-30 Dkr46.05 Million
≈ $7.20 Million
Dkr-2.87 Million
≈ $-449.66K
-0.062x -27.18%
2021-09-30 Dkr42.57 Million
≈ $6.66 Million
Dkr-2.09 Million
≈ $-326.84K
-0.049x +83.01%
2020-09-30 Dkr34.28 Million
≈ $5.36 Million
Dkr-9.90 Million
≈ $-1.55 Million
-0.289x -6981.66%
2019-09-30 Dkr67.16 Million
≈ $10.51 Million
Dkr-274.00K
≈ $-42.87K
-0.004x +79.96%
2018-09-30 Dkr77.57 Million
≈ $12.14 Million
Dkr-1.58 Million
≈ $-247.05K
-0.020x +64.80%
2017-09-30 Dkr85.09 Million
≈ $13.31 Million
Dkr-4.92 Million
≈ $-769.93K
-0.058x -2992.17%
2016-09-30 Dkr96.78 Million
≈ $15.14 Million
Dkr-181.00K
≈ $-28.32K
-0.002x +93.66%
2015-09-30 Dkr99.53 Million
≈ $15.57 Million
Dkr-2.94 Million
≈ $-459.67K
-0.030x +39.77%
2014-09-30 Dkr97.95 Million
≈ $15.32 Million
Dkr-4.80 Million
≈ $-750.99K
-0.049x -189.26%
2013-09-30 Dkr-105.44 Million
≈ $-16.50 Million
Dkr-5.79 Million
≈ $-905.73K
0.055x +118.92%
2012-09-30 Dkr36.39 Million
≈ $5.69 Million
Dkr-10.56 Million
≈ $-1.65 Million
-0.290x -304.66%
2011-09-30 Dkr79.67 Million
≈ $12.46 Million
Dkr-5.71 Million
≈ $-893.84K
-0.072x +78.56%
2010-09-30 Dkr53.06 Million
≈ $8.30 Million
Dkr-17.75 Million
≈ $-2.78 Million
-0.334x -2303.51%
2009-09-30 Dkr53.47 Million
≈ $8.37 Million
Dkr-744.00K
≈ $-116.40K
-0.014x --

About Pharma Equity Group A/S Cl A

CO:PEG Denmark Biotechnology
Market Cap
$13.60 Million
Dkr86.91 Million DKK
Market Cap Rank
#26122 Global
#120 in Denmark
Share Price
Dkr0.07
Change (1 day)
+3.81%
52-Week Range
Dkr0.07 - Dkr0.12
All Time High
Dkr2.81
About

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment… Read more